Description
Bacillus Clausii
Generic Medicine InfoPatient Medicine Information
This information is not country-specific. Please refer to the local prescribing information.
Generic Medicine Info
Indications and Dosage Oral Adult: As 2×109 spores/5 mL oral suspension or 2×109 spores/capsule: 2-3 vials or capsules daily at 3-4 hours intervals. |
Special Precautions Immunocompromised patients (e.g. premature infants). Children. Pregnancy and lactation. Not intended for inj or administration in any other way. |
Adverse Reactions Immune system disorders: Hypersensitivity reactions (e.g. rash, urticaria, angioedema). |
Patient Counseling Information Administer in the interval between 1 dose of antibiotic and the next during antibiotic treatment. |
Action Description: Bacillus clausii, a probiotic, is a spore-forming bacterium part of the normal gut flora with no pathogenic properties. It inhibits the growth of pathogens in the gastrointestinal tract via 3 distinct mechanism: colonisation, immunostimulation and antimicrobial properties. Bacillus clausii spores have high resistance to acidic conditions of the stomach and can reach the intestinal tract intact wherein they are transformed into metabolically active vegetative cells; they also contribute to restore the balance of the intestinal bacterial flora. Bacillus clausii is also capable of producing vitamins, particularly the group B vitamins, which contribute to correct the dysvitaminosis caused by use of antibiotics and chemotherapeutic agents. |
Storage Oral suspension: Store below 30°C. Cap: Store below 25°C. |
MIMS Class |
References Jayanthi N and Ratna Sudha M. Bacillus clausii – The Probiotic of Choice in the Treatment of Diarrhoea. 5(4):1-4. doi: 10.4172/2157-7595.1000211. Accessed 18/07/2019 Anon. Bacillus clausii. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/07/2019. Erceflora (Sanofi S.p.A.). MIMS Philippines. http://www.mims.com/philippines. Accessed 18/07/2019. |
Disclaimer: This information is independently developed by MIMS based on Bacillus clausii from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com